Pranita D Tamma1, Samuel L Aitken2, Robert A Bonomo3, Amy J Mathers4, David van Duin5, Cornelius J Clancy6. 1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 3. Medical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, University Hospitals Cleveland Medical Center and Departments of Medicine, Pharmacology, Molecular Biology, and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA. 4. Departments of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA. 5. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 6. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: Antimicrobial-resistant infections are commonly encountered in US hospitals and result in significant morbidity and mortality. This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). METHODS: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated common questions regarding the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Based on review of the published literature and clinical experience, the panel provide recommendations and associated rationale for each recommendation. Because of significant differences in the molecular epidemiology of resistance and the availability of specific anti-infective agents globally, this document focuses on treatment of antimicrobial-resistant infections in the United States. RESULTS: Approaches to empiric treatment selection, duration of therapy, and other management considerations are briefly discussed. The majority of guidance focuses on preferred and alternative treatment recommendations for antimicrobial-resistant infections, assuming that the causative organism has been identified and antibiotic susceptibility testing results are known. Treatment recommendations apply to both adults and children. CONCLUSIONS: The field of antimicrobial resistance is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. This guidance document is current as of 17 September 2020. Updates to this guidance document will occur periodically as new data emerge. Furthermore, the panel will expand recommendations to include other problematic gram-negative pathogens in future versions. The most current version of the guidance including the date of publication can be found at www.idsociety.org/practice-guideline/amr-guidance/.
BACKGROUND: Antimicrobial-resistant infections are commonly encountered in US hospitals and result in significant morbidity and mortality. This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). METHODS: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated common questions regarding the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Based on review of the published literature and clinical experience, the panel provide recommendations and associated rationale for each recommendation. Because of significant differences in the molecular epidemiology of resistance and the availability of specific anti-infective agents globally, this document focuses on treatment of antimicrobial-resistant infections in the United States. RESULTS: Approaches to empiric treatment selection, duration of therapy, and other management considerations are briefly discussed. The majority of guidance focuses on preferred and alternative treatment recommendations for antimicrobial-resistant infections, assuming that the causative organism has been identified and antibiotic susceptibility testing results are known. Treatment recommendations apply to both adults and children. CONCLUSIONS: The field of antimicrobial resistance is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. This guidance document is current as of 17 September 2020. Updates to this guidance document will occur periodically as new data emerge. Furthermore, the panel will expand recommendations to include other problematic gram-negative pathogens in future versions. The most current version of the guidance including the date of publication can be found at www.idsociety.org/practice-guideline/amr-guidance/.
Authors: Max W Adelman; Chris W Bower; Julian E Grass; Uzma A Ansari; Elizabeth A Soda; Isaac See; Joseph D Lutgring; Jesse T Jacob Journal: Open Forum Infect Dis Date: 2021-12-29 Impact factor: 3.835
Authors: Heather I Henderson; Laura Ruegsegger; Kevin Alby; Jason R Smedberg; Bravada M Hill; Dylan Brown; David A Wohl; Sonia Napravnik; David Van Duin Journal: JAC Antimicrob Resist Date: 2022-08-02
Authors: Laura Ruegsegger; Jamie Xiao; Arash Naziripour; Trey Kanumuambidi; Dylan Brown; Felicia Williams; Steven H Marshall; Susan D Rudin; Kelly Yen; Tingyu Chu; Liang Chen; Emanuele Sozzi; Luther Bartelt; Barry Kreiswirth; Robert A Bonomo; David van Duin Journal: Antimicrob Agents Chemother Date: 2022-09-06 Impact factor: 5.938
Authors: Majed F Alghoribi; Moayad Alqurashi; Liliane Okdah; Bassam Alalwan; Yahya S AlHebaishi; Abdulmajeed Almalki; Maha A Alzayer; Abdulrahman A Alswaji; Michel Doumith; Mazin Barry Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Mary B Ford; Katrin Mende; Susan J Kaiser; Miriam L Beckius; Dan Lu; Jason Stam; Ping Li; Laveta Stewart; David R Tribble; Dana M Blyth Journal: Mil Med Date: 2022-03-28 Impact factor: 1.563